BAR­DA bets $86M on Con­tra­Fec­t's PhI­II bid against drug-re­sis­tant Staph

Be­fore they be­came known as the Covid-19 Vac­cines Fund­ing Agency, BAR­DA de­vot­ed much of its drug de­vel­op­ment ef­forts to ad­vanc­ing drugs for a dif­fer­ent out­break: The rise of drug-re­sis­tant bac­te­ria.

Those ef­forts, as BAR­DA re­minds Con­gress in an­nu­al re­ports, have led to two dif­fer­ent ap­provals: Achao­gen’s Zem­dri and Melin­ta’s Vabomere. Now BAR­DA is look­ing to push a third past the fin­ish­ing line, promis­ing Con­tra­Fect up to $86 mil­lion for their on­go­ing Phase III tri­al for Staph in­fec­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER